12.1 Non-Sterile Compounding & USP <795> Standards

12.1 Non-Sterile Compounding & USP <795> Standards

Compounding is a foundational aspect of pharmacy practice that provides customized medications tailored to the unique clinical needs of individual patients when commercially manufactured products are unavailable, unsuitable, or clinically contraindicated. Following the catastrophic 2012 fungal meningitis outbreak linked to the New England Compounding Center (NECC), Congress enacted the Drug Quality and Security Act (DQSA) of 2013, fundamentally overhauling federal compounding jurisprudence. In Utah, compounding practice is regulated under the Utah Pharmacy Practice Act (Utah Code Ann. § 58-17b-101 et seq.) and DOPL's compounding rule, Utah Admin. Code R156-17b-614e. That rule requires compliance with USP <795>, <797>, and <825> and sets Utah's own schedule and modifications for USP <800>. Candidates preparing for the Utah MPJE must master the statutory divide between traditional pharmacy compounding and outsourcing facilities, facility sanitation and water standards, formulation documentation, and strict beyond-use dating (BUD) limits.

Regulatory Framework: DQSA Section 503A vs. Section 503B

The DQSA amended the federal Food, Drug, and Cosmetic Act (FDCA) by establishing a two-tiered statutory architecture that separates traditional pharmacy compounding from commercial-scale sterile and non-sterile compounding operations:

Section 503A Traditional Pharmacy Compounding (21 U.S.C. § 353a)

Section 503A applies to licensed state pharmacies and federal facilities that compound medications pursuant to an individual, patient-specific prescription order:

• Patient-Specific Mandate: A 503A pharmacy must compound upon receipt of a valid prescription order for an identified patient, or in limited quantities before receipt of a valid prescription order (anticipatory compounding) based on a previously observed, regular history of receiving valid prescription orders from a specific prescriber.
• Statutory Exemptions: If a compound complies with Section 503A, it is exempt from three massive FDCA provisions: (1) Current Good Manufacturing Practice (cGMP under 21 U.S.C. § 351(a)(2)(B) and 21 CFR Parts 210/211); (2) FDA premarket approval / New Drug Application (NDA/ANDA) requirements under 21 U.S.C. § 355; and (3) Adequate directions for use labeling mandates under 21 U.S.C. § 352(f)(1).
• Primary Oversight: Regulated primarily by state boards of pharmacy (DOPL in Utah) and must comply with applicable USP compounding chapters (<795>, <797>, <800>).
• Key Restrictions: A 503A pharmacy may not compound preparations that are "essentially copies" of commercially available drug products without a significant change producing an identifiable clinical difference for an individual patient (e.g., removing a preservative causing an allergy, or formulating an oral liquid for a pediatric dysphagic patient). Furthermore, 503A pharmacies are prohibited from distributing more than 5% of their total prescription orders interstate unless their state has entered into a Standard Memorandum of Understanding (MOU) with the FDA.

Section 503B Outsourcing Facilities (21 U.S.C. § 353b)

Section 503B established a voluntary federal registration category for facilities that compound sterile and non-sterile drugs in bulk:

• Office-Use Distribution: 503B facilities may compound and distribute large batches to hospitals, surgery centers, and physician clinics for "office use" without receiving patient-specific prescriptions.
• Regulatory Oversight: Directly regulated and inspected by the FDA on a risk-based schedule.
• Mandatory cGMP Compliance: Unlike 503A pharmacies, 503B outsourcing facilities are strictly subject to full FDA cGMP regulations, including rigorous environmental monitoring, process validation, continuous stability testing, and batch-release sterility testing.
• Exemptions & Prohibitions: Exempt from NDA/ANDA premarket approval and adequate directions for use, but subject to mandatory adverse event reporting within 15 calendar days, biannual electronic reporting of all compounded drug products to the FDA, and specific container labeling ("This is a compounded drug"). Compounding must occur under the direct personal supervision of a licensed pharmacist.

---

Utah Statutory Framework & Incorporation of USP <795>

Under Utah Code § 58-17b-102(18), compounding is preparing, mixing, assembling, packaging, or labeling a limited quantity of a drug, sterile product, or device:

• as the result of a practitioner's prescription or initiative based on the practitioner, patient, and pharmacist relationship;
• for research, teaching, or chemical analysis (not for sale or dispensing); or
• in anticipation of prescriptions based on routine, regularly observed prescribing patterns.

Compounding does not include preparing drugs for sale to another pharmacist or pharmaceutical facility, preparing a dosage form regularly and commonly available from a manufacturer, or preparing a drug withdrawn from the market for safety reasons. DOPL's rule also excludes reconstitution or mixing done according to the manufacturer's approved labeling, and adding therapeutically inert flavoring that does not exceed 5% of the total volume of a commercially available liquid (R156-17b-102(13)).

Under Utah Admin. Code R156-17b-614e, a licensee engaged in sterile or nonsterile compounding must follow USP <797> (except that a smoke study is required only for new construction or when equipment is physically moved within the cleanroom), USP <795>, and USP <825> (radiopharmaceuticals). These standards apply to every Utah pharmacy or licensee that compounds, wherever the patient is located. Consequences:

• Failing to comply with USP <795> or <797> is unprofessional conduct (R156-17b-502(2)).
• Compounding a dosage form commonly available from a manufacturer in the prescribed strength and quantity is unprofessional conduct (§ 58-17b-502(1)(m)).
• A compounded drug that is adulterated or misbranded may not be dispensed (§ 58-17b-502(1)(c)).
• Compounded prescription labels need the generic name and the quantity or concentration of each active ingredient. Sterile parenterals also need the diluent, lot number, and "compounded preparation" (R156-17b-614a(2)).
• DOPL also has an Advisory Pharmacy Compounding Education Committee (R156-17b-203). An out-of-state (Class D) compounding pharmacy must follow USP <795> and <797> and submit recent inspection reports (R156-17b-616; § 58-17b-308(4)).

---

Facility, Equipment & Purified Water Standards

USP <795> mandates that non-sterile compounding occur in a designated, controlled environment designed to prevent mix-ups, cross-contamination, and microbial adulteration:

1. Dedicated Compounding Space: The compounding area must be separate and distinct from routine dispensing, order processing, and patient counseling areas. It must be situated away from high-traffic flow, external doors, air vents, and direct sunlight.
2. Surfaces and Cleaning: Work surfaces, walls, counters, and floors must be smooth, non-porous, crack-free, and impervious to water, sanitizing agents, and active pharmaceutical ingredients. Equipment and utensils must be thoroughly cleaned and sanitized immediately before and after each compounding session.
3. Equipment Suitability: Measuring and weighing devices must possess certified accuracy. Balances and other measuring equipment must be suitable for the quantities weighed and must be calibrated and checked according to the manufacturer's instructions and the facility's SOPs. Utensils such as spatulas, stirring rods, mortars, and pestles must be constructed of non-reactive, non-adsorbing materials (such as stainless steel, porcelain, or borosilicate glass).
4. Water Quality Requirements: Water is the most common raw material and solvent used in pharmacy compounding, requiring rigorous quality distinction:
   • Potable (Drinking) Water: Supplied by a municipal or verified drinking water system; legally permitted only for hand washing and the initial washing and rinsing of compounding utensils.
   • USP Purified Water: Water purified by deionization, distillation, or reverse osmosis; strictly mandatory for the formulation of non-sterile aqueous preparations and for the final rinsing of all compounding equipment and utensils.

---

Master Formulation Record (MFR) vs. Compounding Record (CR)

A critical documentation mandate tested on the Utah MPJE is the strict administrative dichotomy between the Master Formulation Record (MFR) and the Compounding Record (CR) under USP <795>:

Master Formulation Record (MFR) — The Blueprint / Recipe

The MFR is the standard reference formulation created before compounding a preparation for the first time or when preparing batches. It represents the validated master recipe that ensures consistent potency, quality, and reproducibility across different compounding personnel. An MFR must contain:

• Official or assigned name, strength, and dosage form of the preparation.
• Calculations used to determine ingredient quantities.
• Exact chemical names, grades, and quantities of all active pharmaceutical ingredients (APIs) and excipients.
• Complete list of necessary equipment, balances, and utensils.
• Step-by-step mixing and compounding instructions (including order of addition, mixing durations, temperatures).
• Prescribed container-closure system (e.g., amber glass bottle with child-resistant closure).
• Detailed storage requirements (e.g., "refrigerate at 2°C to 8°C; protect from light").
• Quality control (QC) criteria and expected physical description (e.g., "uniform, opaque white suspension").
• Assigned beyond-use date (BUD) and the scientific rationale or literature citation supporting the assigned BUD.

Compounding Record (CR) — The Specific Execution Log

The Compounding Record is the historical execution log created during each specific compounding event. It documents the individual batch or single-prescription execution of an existing MFR. A CR must include:

• Official or assigned name, strength, and dosage form (referencing the specific MFR ID).
• Master Formulation Record reference identifier.
• Names, manufacturers, lot numbers, and expiration dates of each specific raw ingredient and chemical lot used.
• Actual measured weights and volumes of each component (including initialed dual-checks).
• Total quantity or yield compounded.
• Assigned internal batch lot number and unique prescription number.
• Assigned beyond-use date (BUD) and date/time of preparation.
• Physical description and quality control testing results of the finished preparation.
• Identity and signature/initials of the pharmacy technician or intern who compounded the preparation.
• Identity and signature/initials of the licensed pharmacist who conducted the final verification.

Loading diagram...

---

Beyond-Use Dating (BUD) Limits Under Revised USP <795>

The Beyond-Use Date (BUD) represents the date or hour after which a compounded preparation may not be used, stored, or transported. Under revised USP <795>, default beyond-use dating limits have been established based on the dosage form's physical state, presence of water, and presence of antimicrobial preservatives, in the absence of formulation-specific stability-indicating study data:

The Shortest Component Expiration Constraint

A core USP <795> rule is that the assigned beyond-use date may not exceed the earliest expiration date of any starting component used in the compound:

Assigned BUD = the earlier of (1) the USP <795> default limit or (2) the earliest component expiration date.

If a pharmacist compounds pediatric spironolactone oral capsules (a solid dosage form eligible for a 180-day default BUD), but the bulk spironolactone raw powder has a manufacturer expiration date occurring in 42 days, the maximum legal BUD that may be assigned is 42 days.

Extending Beyond-Use Dates

A pharmacy may assign a BUD exceeding the default USP <795> limits only when supported by a published USP-NF compounded preparation monograph or by valid, stability-indicating analytical testing performed specifically on that identical formulation, container-closure system, and storage condition.

---

Common MPJE Traps & Scenario Analysis

1. The Commercial Copy Prohibition: A physician writes a prescription for omeprazole 20 mg compounded capsules because the patient's insurance denies the commercial 20 mg capsule. Exam Trap: Under Section 503A, pharmacies cannot compound essentially copies of commercially available drugs to save patients money or circumvent third-party payer formularies. Compounding is only permitted if there is an identifiable medical difference (e.g., severe allergy to an inactive dye or excipient, or unavailability due to an official FDA shortage listing).
2. Reconstitution vs. Compounding: Reconstituting a commercial antibiotic powder (such as amoxicillin 250 mg/5 mL suspension) strictly in accordance with the manufacturer's package insert is dispensing/reconstitution, not compounding under USP <795>. However, adding unapproved flavoring agents, altering the diluent, or combining two commercial liquids constitutes compounding and triggers USP <795> compliance.
3. Office-Use Supply Requests: A local podiatrist requests 50 tubes of compounded urea 40% ointment to keep in the clinic for in-office debridement procedures. Exam Trap: Utah's office-use statute (§ 58-17b-624) allows labeled "for office use only" sales of non-controlled compounded drugs for administration in the office, but only in compliance with federal law. Under section 503A, a traditional pharmacy's compounding must be based on patient-specific prescriptions (or limited anticipatory compounding), so bulk office stock generally calls for a 503B outsourcing facility.
4. Aqueous Oral Suspension Storage: A technician labels a non-preserved aqueous oral suspension of baclofen with a 14-day BUD and "Store at Room Temperature." Exam Trap: Under USP <795>, non-preserved aqueous oral dosage forms must be stored in the refrigerator (2°C to 8°C) to qualify for the 14-day BUD limit.